Global Migraine It’s Market– Industry Trends and Forecast to 2027

Author: Rahul Kanthale

Migraine - Market Insights, Epidemiology and Market Forecast-2027

Wiseguyreports.Com Adds "Migraine - Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2027" To Its Research Database.

Description:

DelveInsight’s ‘Migraine - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Migraine in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Migraine from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Migraine - Disease Understanding and Treatment Algorithm

Migraine is an inherited tendency to have headaches with sensory disturbance. It’s an instability in the way the brain deals with incoming sensory information, and that instability can become influenced by physiological changes like sleep, exercise and hunger. It is one of the most common and most prevalent neurological disease with extremely incapacitating neurological symptoms. It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face.

The DelveInsight Migraine market report gives the thorough understanding of the Migraine by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Migraine in the US, Europe, and Japan.

Migraine Epidemiology

The Migraine epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Type Specific Prevalence (Acute, Chronic and Episodic), and Diagnosed and Treatable Population] scenario of Migraine in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to the US Centers for Disease Control, self-reported migraine prevalence in the United States increased by 60%, from 25.8 to 41 per 1000 person-years between 1981 and 1989. The World Health Organization’s disability rating for migraine, ranks it as the 19th most common reason for disability.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3320974-migraine-market-insights-epidemiology-and-market-forecast-2027

Migraine Drug Chapters

This segment of the Migraine report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

On the basis of treatment type, the Migraine drugs market is broadly classified into two types of therapies: pain-relieving and preventive. Recently in May 2018, U.S. FDA approved a new drug, Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.

Migraine Market Outlook

The Migraine market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key players such as IMPAX Laboratories, Inc., Zosano Pharma Corporation, Biohaven Pharmaceuticals, Inc., Allergan and many others are involved in developing therapies for Migraine. Expected launch of emerging therapies such as IPX229 (IMPAX Laboratories, Inc.) and M207/ADAM Zolmitriptan (Zosano Pharma Corporation), Rimegepant (Biohaven Pharmaceuticals, Inc.), Ubrogepant (Allergen) etc. are expected to create a noticeable increase in the market size of Migraine in the upcoming years.

Migraine Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

  • p>
Migraine Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Migraine Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Sub-type Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Download Detail Report@ https://www.wiseguyreports.com/reports/3320974-migraine-market-insights-epidemiology-and-market-forecast-2027

Table of Content

  1. Report Introduction

  2. Migraine Market Overview at a Glance

    2.1. 7 Major Market Size of Migraine in 2017

    2.2. 7 Major Market Size of Migraine in 2027

  3. Disease Background and Overview: Migraine

    3.1. Introduction

    3.2. Causes

    3.3. Pathophysiology

    3.4. Symptoms

    3.5. Risk Factor

    3.6. Diagnosis

  4. Epidemiology and Patient Population

    4.1. Assumptions and Caveats

    4.2. 7MM Prevalent cases of Migraine (2016-2027)

    4.3. Type specific prevalent cases of Migraine in 7MM (2016-2027)

    4.4. Diagnosed and Treatable cases of Migraine in 7MM (2016-2027)

  5. Migraine: Country-Wise Epidemiology

    5.1. United States

    5.1.1. Prevalent cases of Migraine in the US (2016-2027)

    5.1.2. Type specific prevalent cases of Migraine in the US (2016-2027)

    5.1.3. Diagnosed and Treatable cases of Migraine in the US (2016-2027)

    5.2. EU-5

    5.2.1. Germany

    5.2.1.1. Prevalent cases of Migraine in Germany (2016-2027)

    5.2.1.2. Type specific prevalent cases of Migraine in Germany (2016-2027)

    5.2.1.3. Diagnosed and Treatable cases of Migraine in Germany (2016-2027)

    5.2.2. France

    5.2.2.1. Prevalent cases of Migraine in the France (2016-2027)

    5.2.2.2. Type specific prevalent cases of Migraine in France (2016-2027)

    5.2.2.3. Diagnosed and Treatable cases of Migraine in France (2016-2027)

    5.2.3. Italy

    5.2.3.1. Prevalent cases of Migraine in Italy (2016-2027)

    5.2.3.2. Type specific prevalent cases of Migraine in Italy (2016-2027)

    5.2.3.3. Diagnosed and Treatable cases of Migraine in Italy (2016-2027)

    5.2.4. Spain

    5.2.4.1. Prevalent cases of Migraine in Spain (2016-2027)

    5.2.4.2. Type specific prevalent cases of Migraine in Spain (2016-2027)

    5.2.4.3. Diagnosed and Treatable cases of Migraine in Spain (2016-2027)

    5.2.5. United Kingdom

    5.2.5.1. Prevalent cases of Migraine in the UK (2016-2027)

    5.2.5.2. Type specific prevalent cases of Migraine in the UK (2016-2027)

    5.2.5.3. Diagnosed and Treatable cases of Migraine in the UK (2016-2027)

    5.3. Japan

    5.3.1. Prevalent cases of Migraine in Japan 2016-2027)

    5.3.2. Type specific prevalent cases of Migraine in Japan (2016-2027)

    5.3.3. Diagnosed and Treatable cases of Migraine in Japan (2016-2027)

Continued………..

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)